Colesevelam: A New Bile Acid Sequestrant

Heart Disease

Volumn 3, Issue 1, 2001, Pages 63-70

  Wong, Nina N ^a,b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

Bile acid resin; Bile acid sequestrant; Cholesterol; Colesevelam

Indexed keywords

ALLYLAMINE; CHOLAGOGUE; COLESEVELAM; DRUG DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGE; BLOOD; CARDIOVASCULAR DISEASE; DOSE RESPONSE; DRUG COMBINATION; DRUG COST; DRUG EFFECT; DRUG INTERACTION; ECONOMICS; HUMAN; PREVALENCE; REVIEW; TREATMENT OUTCOME; UNITED STATES;

AGE FACTORS; ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLAGOGUES AND CHOLERETICS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COSTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PREVALENCE; TREATMENT OUTCOME; UNITED STATES;

EID: 0035240368     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00132580-200101000-00009     Document Type: Article

References (46)

1. Anonymous. Cardiovascular diseases - mortality. Available at: http://www. americanheart.org/statistics/03cardio.html. Accessed on September 13, 2000.
2. Public Health Service. Deaths. Final data for National Vital Statistics Report. 2000; 48:5-7. Available at: http://www.cdc.gov/nchs/releases/00news/finaldeath98.htm. Accessed on September 29, 2000.
3. Anonymous. Leading causes of death - 1997. Available at: http://www. americanheart.org/statistics/biostats/biolc.htm. Accessed on September 13, 2000.
4. Gotto AM Jr. Cholesterol management in theory and practice. Circulation 1997;96:4424-4430.
5. Grundy SM, Balady GJ, Criqui MH, et al. Primary prevention of coronary heart disease: guidance from Framingham. A statement for Healthcare professionals from the American Heart Association Task Force on Risk Reduction. Circulation 1998;97:1876-1887.
6. Verschuren WM, Jacobs DR, Bloembery BP, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures: twenty-five year follow-up of the seven countries study. JAMA 1995;274:13-16.
7. Eisenberg DA. Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials. Am J Med 1998;104 (Suppl 2A):2S-5S.
8. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in the incidence of coronary artery disease. JAMA 1984;251:351-364.
9. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-374.
10. Hjermann I, Holme I, Leren P. Oslo study diet and anti-smoking trial: results after 102 months. Am J Med 1986;80(Suppl 2A):7-11.
11. Frick MH, Elo O, Haapa K, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317:1237-1245.
12. World Health Organization European Collaborative Group. European collaborative trial of multifactorial prevention of coronary heart disease: final report on the 6-year results. Lancet 1986;1:869-872.
13. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
14. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipolniacin on coronary atherosclerosis. JAMA 1990;264:3013-3017.
15. Strandberg TE, Salomaa VV, Naukkarinen VA, et al. Long-term mortality after 5-year multifactorial primary prevention of cardiovascular diseases in middle-aged men. JAMA 1991;266:1225-1229.
16. Dorr AE, Gundersen K, Schneider JC Jr, et al. Colestipol hydrochloride in hypercholesterolemic patients: effect on serum cholesterol and mortality. J Chron Dis 1978;31:5-14.
17. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
18. Tonkin AM. Management of the long-term intervention with pravastatin in ischemic disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995;76:107C-112C.
19. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8:1245-1255.
20. Ginsberg HN. Update on the treatment of hypercholesterolemia, with a focus on HMG-CoA reductase inhibitors and combination regimens. Clin Cardiol 1995;18:307-315.
21. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, National Cholesterol Education Program. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 1993;269:3015-3023.
22. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89:1329-1445.
23. Centers for Disease Control and Prevention/National Center for Health Statistics and American Heart Association. National Health and Nutrition Examination Survey III (NHANES III). From 00hus067.pdf. Available at: http://www.cdc.gov/ncbs/fastats/cholest/htm. Accessed on September 13, 2000.
24. Antilipidemic agents. In: Drug Facts and Comparisons. St. Louis, MO. Facts and Comparisons; 2000:532.
25. Talbert RL. Hyperlipidemia. In: DiPiro JT, Talbert KL, Yee GC, et al (eds). Pharmacotherapy: A Pathophysiologic Approach. 4th ed. Stamford, CT: Appleton and Lange; 1999:350-361.
26. Schafer EJ, Levy RI. Pathogenesis and management of lipoprotein disorders. N Engl J Med 1985;312:1300-1310.
27. Farmer JA, Gotto AM Jr. Choosing the right lipid-regulating agent: a guide to selection. Drugs 1996;52:649-661.
28. Anonymous. Comparative drug charts. Lipid-lowering agents. In: Lacy CF, Armstrong LL, Goldman MP, et al (eds). Drug Information Handbook. 7th ed. Hudson, OH: Lexi-Comp, Inc; 1999-2000:1327.
29. Pan HY, DeVault AR, Swites BJ, et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther 1990;48:201-207.
30. McEvoy GK (ed). American Hospital Formulary Service Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2000:1621-1625, 1628-1631.
31. WelChol [package insert]. New York, NY: Sankyo Pharmaceuticals, Inc., 2000.
32. Shepherd J, Packard CJ, Bicker S, et al. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N Engl J Med 1980;302:1219-1222.
33. Carrilho AJ, Medina WL, Nakandakare ER, et al. Plasma cholesteryl ester transfer protein is lowered by treatment of hypercholesterolemia with cholestyramine. Clin Pharmacol Ther 1997;62.82-88.
34. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (CholestaGel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159:1893-1900.
35. Heller DP, Stevens RE, Davidson D, et al. Absorption of 14C-colesevelam hydrochloride in healthy male and female adult volunteers [abstract]. American Association of Pharmaceutical Scientists, Annual Meeting and Exposition, November 14-18, 1999; New Orleans, LA.
36. DRUGDEX® Editorial Staff. Colesevelam. Micromedex® Healthcare Series [monograph on CD-ROM]. Vol. 105. Englewood, CO: Micromedex, December 1999.
37. Insull W, Toth P, Hunninghake D, et al. Colesevelam, a novel, potent, polymeric bile acid sequestrant significantly lowers LDL cholesterol [abstract]. The 5th International Symposium on Multiple Risk Factors in Cardiovascular Disease: Global Assessment and Intervention; October 28-31, 1999; Venice, Italy.
38. Ose L, MacMahon M, Theisen K, et al. Once per day and split dosing of colesevelam in patients with type IIa hypercholesterolemia [abstract]. The 5th International Symposium on Multiple Risk Factors in Cardiovascular Disease: Global Assessment and Intervention; October 28-31, 1999; Venice, Italy.
39. Mesner CH, Burke SK, Olson T. Effect of CholestaGel and lovastatin alone and in combination for the treatment of hypercholesterolemia [abstract]. The 13th International Symposium on Drugs Affecting Lipid Metabolism; May 30-June 3, 1998; Florence, Italy.
40. Hunninghake DB, Probstfield JL, Crow LO, et al. Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipidemia. Metabolism 1981;30:605-609.
41. Vecchio TJ, Linden CV, O'Connell MJ, et al. Comparative efficacy of colestipol and clofibrate in type IIa hyperlipoproteinemia. Arch Intern Med 1982;142: 721-723.
42. Anonymous. FDA approves WelChol (colesevelam HCA) for lowering LDL cholesterol. Drug Updates, June 12, Available at: http://home.mdconsult.com/das/news/body/drug/18491543/41889/1.html?nid= 41889. Accessed on August 4, 2000.
43. Adis R&D Profile. Colesevelam. GT 31104, Cholestagel. Drugs RD 1999;1: 479-480.
44. Anonymous. GelTex Pharmaceuticals, Inc. and Sankyo Parke Davis announce FDA marketing approval for WelChol (colesevelam HCl), a novel, non-systemic lipid lowering agent. Press Releases, May 30, 2000. Available at: http://www. geltex.com/pressreleases/pr053000.html. Accessed on August 4, 2000.
45. Hunninghake DB, Stein EA, Fraser Bremner W, et al. Dose-response study of colestipol tablets in patients with moderate hypercholesterolemia. Am J Ther 1995;2:180-189.
46. Hoogerbrugge N, Mol MJ, Van Dormaal JJ, et al. The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolemia. J Intern Med 1990;228:261-266.